Brief: MaxCyte Inc and Editas Medicine Announce License Agreement For Engineered Cell Medicines
07/10/2019 08:05
Oct 7 (Reuters) - MaxCyte Inc MXCT.L :
* MAXCYTE INC - EDITAS MEDICINE AND CO ANNOUNCE CLINICAL AND
COMMERCIAL LICENSE AGREEMENT FOR ENGINEERED CELL MEDICINES
Source text for Eikon: ID:nRSG9473Oa
Further company coverage: MXCT.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: Maxcyte And Allogene Therapeutics Sign Clinical And Commercial License Agreement To Enable The Advancement Of Allogeneic Car T (Allocar T™) Therapies
Brief: Maxcyte Signs Agreement With KSQ Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Agreement with KSQ Therapeutics